Global Healthcare Study on Atopic Dermatitis

NCT07659756 · tracked via the Priya Life Science Switzerland tracker

Sponsor

Julia Tatjana Maul

Phase

Observational

Started

2025-01-01

Last updated

2026-06-22

Condition(s) studied

Atopic Dermatitis (AD)Atopic Dermatitis (Eczema)

Study summary

The Global Healthcare Study on Atopic Dermatitis (GHSAD) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with atopic dermatitis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.

Eligibility

Sex

ALL

Min age

14 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Signed General Consent Form, or equivalent document * Confirmed diagnosis of Atopic Dermatitis Exclusion Criteria: * Inability to provide informed consent. * Datasets with ambiguous or unclear diagnosis.

Primary outcome measure(s)

Eczema Area and Severity Index (EASI) — Baseline and follow-up visits every 6-12 months for up to 5 years.
Clinician-assessed measure of atopic dermatitis severity based on extent and severity of eczema signs; total score ranges from 0 to 72, with higher scores indicating more severe disease.

Trial sites (1)

Facility	City	Region	Status
University of Zurich	Zurich	Switzerland	Recruiting

More Julia Tatjana Maul trials in Switzerland

Global Healthcare Study on Hidradenitis Suppurativa Recruiting

Global Healthcare Study on Psoriasis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07659756 on ClinicalTrials.gov ↗ ← All trials in Switzerland